129 related articles for article (PubMed ID: 15793124)
1. Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.
Marquis JF; Hardy I; Olivier M
Antimicrob Agents Chemother; 2005 Apr; 49(4):1441-6. PubMed ID: 15793124
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
[TBL] [Abstract][Full Text] [Related]
3. An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3,3'-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme.
Roy A; Das BB; Ganguly A; Bose Dasgupta S; Khalkho NV; Pal C; Dey S; Giri VS; Jaisankar P; Dey S; Majumder HK
Biochem J; 2008 Jan; 409(2):611-22. PubMed ID: 17922678
[TBL] [Abstract][Full Text] [Related]
4. Resistance mechanism development to the topoisomerase-I inhibitor Hoechst 33342 by Leishmania donovani.
Marquis JF; Hardy I; Olivier M
Parasitology; 2005 Aug; 131(Pt 2):197-206. PubMed ID: 16145936
[TBL] [Abstract][Full Text] [Related]
5. A pentapeptide signature motif plays a pivotal role in Leishmania DNA topoisomerase IB activity and camptothecin sensitivity.
Prada CF; Alvarez-Velilla R; Diaz-González R; Prieto C; Pérez-Pertejo Y; Balaña-Fouce R; Reguera RM
Biochim Biophys Acta; 2012 Dec; 1820(12):2062-71. PubMed ID: 23000572
[TBL] [Abstract][Full Text] [Related]
6. Mutational study of the "catalytic tetrad" of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: Role of Asp-353 and Asn-221 in camptothecin resistance.
Diaz-González R; Pérez-Pertejo Y; Pommier Y; Balaña-Fouce R; Reguera RM
Biochem Pharmacol; 2008 Sep; 76(5):608-19. PubMed ID: 18655776
[TBL] [Abstract][Full Text] [Related]
7. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
8. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
9. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
10. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
Roy A; BoseDasgupta S; Ganguly A; Jaisankar P; Majumder HK
Antimicrob Agents Chemother; 2009 Jun; 53(6):2589-98. PubMed ID: 19332675
[TBL] [Abstract][Full Text] [Related]
12. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
15. A tyrosyl DNA phosphodiesterase 1 from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo I-DNA covalent complexes.
Banerjee B; Roy A; Sen N; Majumder HK
Mol Microbiol; 2010 Oct; 78(1):119-37. PubMed ID: 20659295
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the presence of R250G mutation at the ATPase domain of topoisomerase II in an arsenite-resistant Leishmania donovani exhibiting a differential drug inhibition profile.
Singh G; Thakur M; Chakraborti PK; Dey CS
Int J Antimicrob Agents; 2009 Jan; 33(1):80-5. PubMed ID: 18805675
[TBL] [Abstract][Full Text] [Related]
17. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
18. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
[TBL] [Abstract][Full Text] [Related]
19. A novel active DNA topoisomerase I in Leishmania donovani.
Villa H; Otero Marcos AR; Reguera RM; Balaña-Fouce R; García-Estrada C; Pérez-Pertejo Y; Tekwani BL; Myler PJ; Stuart KD; Bjornsti MA; Ordóñez D
J Biol Chem; 2003 Feb; 278(6):3521-6. PubMed ID: 12444094
[TBL] [Abstract][Full Text] [Related]
20. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
